Group Leader
Sami Ventelä, MD, PhD
Specialist in otorhinolaryngology
Email: satuve [at] utu.fi
Contact Information
Turku Bioscience P.O. Box 123, BioCity
Street addr. Tykistökatu 6 B, 4th floor
FIN-20521
Turku, Finland
Personnel
Publications
Olotu O, Koskenniemi AR, Ma L, Paramonov V, Laasanen S, Louramo E, Bourgery M, Lehtiniemi T, Laasanen S, Rivero-Müller A, Löyttyniemi E, Sahlgren C, Westermarck J, Ventelä S, Visakorpi T, Poutanen M, Vainio P, Mäkelä JA, Kotaja N. Germline-specific RNA helicase DDX4 forms cytoplasmic granules in cancer cells and promotes tumor growth. Cell Rep. 23;43(7):114430, 2024.
Identification of stemness-related glycosylation changes in head and neck squamous cell carcinoma. Routila E, Mahran R, Salminen S, Irjala H, Haapio E, Kytö E, Ventelä S, Petterson K, Routila J, Gidwani K, Leivo J. BMC Cancer. 10;24(1):443, 2024.
Lehtinen N, Suhonen J, Rice K, Välimäki E, Toriseva M, Routila J, Halme P, Rahi M, Irjala H, Leivo I, Kallajoki M, Nees M, Kuopio T, Ventelä S, Rantala JK. Assessment of targeted therapy opportunities in sinonasal cancers using patient-derived functional tumor models. Transl Oncol. 23;44:101935, 2024.
Pakkanen P, Ilmarinen T, Halme E, Irjala H, Koivunen P, Pukkila M, Ventelä S, Almangush A, Birkman EM, Lindgren O, Pohjolainen V, Sjöblom N, Haglund C, Hagström J, Aaltonen LM. Programmed death-ligand 1 and tumor-infiltrating lymphocytes (TILs) – low TIL density may predict poorer long-term prognosis in T1 laryngeal cancer. Virchows Arch. 485(2):315-322, 2024
Tuominen S, Nissi L, Kukkula A, Routila J, Huusko T, Leivo I, Minn H, Irjala H, Löyttyniemi E, Ventelä S, Sundvall M, Grönroos T. TSPO is a potential independent prognostic factor associated with cellular respiration and p16 in head and neck squamous cell carcinoma. Front Oncol. 14;13:1298333, 2023
Hyytiäinen A, Korelin K, Toriseva M, Wilkman T, Kainulainen S, Mesimäki K, Routila J, Ventelä S, Irjala H, Nees M, Al-Samadi A, Salo T. The effect of matrices on the gene expression profile of patient-derived head and neck carcinoma cells for in vitro therapy testing. Cancer Cell Int. 24;23(1):147, 2023.
Hyytiäinen A, Mroueh R, Peltonen J, Wennerstrand P, Mäkitie A, Al-Samadi A, Ventelä S, Salo T. Prognostic histological markers in oral tongue squamous cell carcinoma patients treated with (chemo)radiotherapy. APMIS. 131(4):142-151, 2023.
Mylly M, Nissi L, Huusko T, Routila J, Vaittinen S, Irjala H, Leivo I, Ventelä S. Epidemiological study of p16 incidence in head and neck squamous cell carcinoma 2005-2015 in representative Northern European population. Cancers (Basel). 21;14(22):5717, 2022.
Denissoff A, Huusko T, Ventelä S, Niemelä S, Routila J. Exposure to alcohol and overall survival in head and neck cancer: A regional cohort study. Head Neck, 44(10):2109-2117, 2022.
Hieta N, Ventelä S, Kujari H. Korvakäytävän punajäkälä – diagnoosiin varhain kuulon heikkenemisen estämiseksi. Duodecim 138:685-9, 2022.
Routila J, Qiao X, Weltner J, Rantala JK, Carpén T, Hagström J, Mäkitie A, Leivo I, Ruuskanen M, Söderlund J, Rintala M, Hietanen S, Irjala H, Minn H, Westermarck J, Ventelä S. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma. Oral Oncology, 127:105772, 2022.
Pakkanen P, Ilmarinen T, Halme E, Irjala H, Koivunen P, Pukkila M, Ventelä S, Hagström J, Aaltonen LA. T1 glottic laryngeal cancer in Finland – the role of routine follow-up visits in detecting local recurrence. Eur Arch Otorhinolaryngol. 278:4863–4869, 2021.
Routila J, Suvila K, Grénman R, Leivo I, Westermarck J, Ventelä S. Cancer cell line microarray as a novel screening method for discovery of predictive biomarkers for radioresistance in head and neck squamous cell carcinoma. BMC Cancer. 21:868, 2021.
Routila J, Leivo I, Minn H, Westermarck J, Ventelä S. Evaluation of putative prognostic molecular biomarkers in a population-validated Finnish HNSCC patient cohort. Eur Arch Otorhinolaryngol. 278: 4575–4585, 2021.
Khan M, Khaznadar SS, Routila J, Ventelä S, Schmid E, Gebhart B, Becker ET, Roider HG, Perala M, Schmitz AA, Krahn T, von Ahsen O. Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients. Head Neck. 42: 625-635, 2020.